Shree Ram Proteins Board Approves Q1 FY27 Results, Year-End FY26 Audited Results
Shree Ram Proteins approved unaudited Q1 FY27 results and audited FY26 results on August 17, 2026. Auditors issued an adverse opinion due to going concern uncertainty, loan defaults, and auction of assets. The company faces a severe working capital shortage and has failed to meet loan installments.
The adverse audit opinion and significant financial distress, including defaults and asset auctions, will have a substantial negative impact on the company's operations, investor confidence, and future prospects.
The auditor's adverse opinion, material uncertainty regarding going concern, loan defaults, asset auction, and working capital shortage indicate a highly negative financial situation for the company.
Shree Ram Proteins Limited announced the outcome of its Board Meeting held on August 17, 2026. The Board considered and approved the unaudited financial results for the quarter ended June 30, 2026. Additionally, the audited financial results for the quarter and year ended March 31, 2026, were also considered, approved, and adopted.
The company's financial statements for the quarter ended June 30, 2026, and the year ended March 31, 2026, have undergone a limited review and audit, respectively, by the statutory auditors. The details of these results, along with the auditors' reports, are enclosed with the outcome. The financial information will also be made available on the company's website under the investors' section.
However, the accompanying auditor's report highlights significant concerns. The auditors have issued an adverse opinion, citing a material uncertainty related to the company's going concern status due to defaults in loan repayments and statutory dues. The company is facing a shortage of funds, and its plant and machinery were auctioned by Union Bank of India. The auditors also noted the absence of balance confirmations, inventory inspections, and impairment assessments. Furthermore, the company has not booked interest for its working capital and term loans as per Ind AS 109. The company had previously withdrawn its Rights Issue in August 2023 due to a lack of investor interest and is currently exploring avenues to mitigate its circumstances.
What to do with a filing like this
Shree Ram Proteins Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shree Ram Proteins Limited. Read the original for the full detail.